PricewaterhouseCoopers

VC investment in biotech sector soars in second quarter

Friday, July 19, 2013 02:18 PM

Venture capitalists invested $6.7 billion in 913 deals in the second quarter of 2013, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Venture capital investments decline in dollars and deal volume in Q3 2012

Friday, October 19, 2012 03:26 PM

Venture capitalists invested $6.5 billion in 890 deals in the third quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

Venture capital investment in life sciences down 9%

Friday, July 20, 2012 02:45 PM

Despite venture capitalists investing $7 billion in 898 deals in the second quarter of 2012—a 17% climb in terms of dollars and an 11% rise in the number of deals compared to the first quarter of 2012, when $6 billion was invested in 809 deals—the life sciences sector (biotechnology and medical devices) saw a 9% drop in funding dollars and a 6% drop in deals from the prior quarter, to $1.4 billion going into 174 deals in Q2.

According to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters, the total number of early stage deals reached the highest quarterly total since Q1 2001, with $2.1 billion going into 410 deals. That’s an 18% increase in dollars and a 28% increase in deals from the prior quarter. Overall, the software industry took in the highest level of funding of all industries with $2.3 billion invested in Q2, the highest investment total for the sector since the Q2 2001.

More... »

Life Sciences venture capital investing falls in first quarter

Tuesday, April 24, 2012 12:21 PM

Venture capitalists invested $5.8 billion in 758 deals in the first quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. Quarterly venture capital (VC) investment activity fell 19% in terms of dollars and 15% in the number of deals compared to the fourth quarter of 2011, when $7.1 billion was invested in 889 deals.

More... »

Venture capital investments in life sciences fall in third quarter

Wednesday, October 19, 2011 01:07 PM

Venture capitalists invested $6.95 billion in 876 deals in the third quarter of 2011, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

Survey: relationship between FDA and life sciences industry deteriorating, delays in review process cited

Monday, December 13, 2010 07:00 AM

Top biopharmaceutical company executives are frustrated with delays and inconsistencies in the Food and Drug Administration (FDA) regulatory review process and are concerned that passage of the healthcare reform law, which gave the already resource-constrained agency more responsibilities, will further complicate drug approvals, according to a new PricewaterhouseCoopers (PwC) survey.

More... »